We are open to “win-win” partnerships that can create value to our dedicated mission and our collaborators around the world.
Hanmi Pharmaceutical Co., Ltd.
Athenex received exclusive rights to Hanmi Pharmaceuticals’ Orascovery technology. Under the terms of the agreement, Athenex has the rights to the development and commercialization of all products derived from the Orascovery program for all indications worldwide, except for Korea.
Hanmi Pharmaceutical Co., Ltd. is headquartered in Seoul, South Korea was established in 1973 and has more than 200 products on the market.
Athenex and PharmaEssentia Corporation executed a targeted license agreement granting PharmaEssentia rights to Athenex’s dual Src/pretubulin inhibitor KX01 ointment, for certain dermatological conditions.
Founded in 2003, PharmaEssentia Corporation is headquartered in Taipei, Taiwan. Its mission is to discover, develop and deliver to the market a range of efficacious, safe and cost-effective therapeutic products for human disease through new drug research and development.
Athenex and Zenith Technology Corporation, through its affiliate ZenRx have executed a collaborative licensing agreement granting Zenith Technology commercial rights to Oraxol and Oratecan in New Zealand and Australia. As part of the collaboration, the first clinical study of an oral form of paclitaxel (Oraxol) was initiated at Dunedin Hospital in Otago, New Zealand.
ZenTech, established in 1987, is an independent contract research organization located in New Zealand.
Eli Lilly and Company
In November 2016, Athenex entered into a collaboration and supply agreement with Eli Lilly and Company to conduct a Phase 1b study that will evaluate the safety and tolerability of Athenex’s Oraxol in combination with Eli Lilly and Company’s CYRAMZA® (ramucirumab), a vascular endothelial growth factor (VEGF) Receptor 2 antagonist, in patients with advanced gastric (stomach) and esophageal cancer.
Athenex and Xiangxue Pharmaceuticals executed a license agreement granting Xiangxue Pharmaceuticals exclusive rights to KX02, for all oncology indications, in the greater China territory and Singapore. Xiangxue Pharmaceuticals will assume all development responsibility and associated costs in the licensed territory for KX02 and will develop the compound for neuro-oncology indications.
Xiangxue Pharmaceutical Co., Ltd (XPH) is a publicly traded pharmaceutical company headquartered in Guangzhou, China. The primary business of the company is the manufacturing and marketing of pharmaceutical products, including herbal medicines, western medicines and biomedical engineering products. The company is actively expanding its product pipeline through research and development efforts and through licensing in areas of unmet medical needs.
Hong Kong Polytechnic University & McGill University
Athenex executed an agreement with Hong Kong Polytechnic University and McGill University for an exclusive license for their patents and know-how on the development of a series of BCRP inhibitor and also the Joint Development of Oral Topotecan in 2015.
Founded in 1821, McGill University is one of Canada’s best-known institutions of higher learning and one of the leading universities in the world. McGill has been ranked 1st in Canada among medical-doctoral universities for the past eleven years (Maclean’s 2016) and is ranked 24th in the world (QS World University Rankings 2015/16). McGill has the highest percentage of PhD students of any Canadian research university and its alumnae include 139 Rhodes Scholars and 12 Nobel Prize winners.
The Hong Kong Polytechnic University is a public university located in Hung Hom, Hong Kong. The history of PolyU can be traced back to 1937, and it assumed full university status in 1994. It is one of the funded institutions of the territory’s University Grants Committee (UGC). PolyU has an international faculty and student community and has developed a global network with more than 440 institutions in 47 countries and regions. PolyU offers 220 postgraduate, undergraduate and sub-degree programs for more than 32,000 students every year.
In December 2017, Athenex entered into a strategic partnership with Almirall, S.A. (BME: ALM) to develop and commercialize Athenex’s KX2-391 in the United States and Europe for the treatment of actinic keratosis.
Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations. The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM).